Author

Marc Ferrante 1

1 University Hospitals Leuven,KU Leuven,BELGIUM

A DRUG-RESISTANT ASSAY CAN BETTER DIRECT THE NEED FOR ADALIMUMAB DOSE-ESCALATION AFTER INDUCTION THERAPY IN ANTI-TNF NAÏVE PATIENTS WITH CROHN’S DISEASE

Gitte Moors, Bram Verstockt, Sumin Bian, Sophie Tops, Vera Ballet, Gert Van Assche, Severine Vermeire, Ann Gils, Marc Ferrante

A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

Marc Ferrante

A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

Marc Ferrante, Valerie Pivorunas, James Butler, Naim Mahi, Nael M. Mostafa, Melanie Ruzek, James Fann, Feng Hong, Xiaohong Cao, Nizar Smaoui, Justin Wade Davis, Jasmina Kalabic, Alexandra Song, Heath M. Guay, Florian Rieder, Julian Panés, Jean-Frédéric Colombel

AEROMONAS SPECIES: AN OPPORTUNISTIC ENTEROPATHOGEN IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES? A SINGLE CENTER COHORT STUDY

Triana Lobaton Ortega, Ilse Hoffman, Severine Vermeire, Marc Ferrante, Jan Verhaegen, Gert Van Assche

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens, Brian Feagan, William J. Sandborn, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Marc Ferrante, Ezequiel Neimark, Peter Bossuyt, Silvio Danese, Alexandra Song, Xiaomei Liao, Tian Feng, Rachel Duan, Sofie Berg, Jean-Frédéric Colombel, Kori Wallace

CIRCULATING B CELL SUBSETS CORRELATE WITH CLINICAL RESPONSE TO ANTI-TNF THERAPY IN IBD

Zhe Li, Severine Vermeire, Dominique Bullens, Marc Ferrante, Kristel Van Steen, Maja Noman, Paul Rutgeerts, Jan L. Ceuppens, Gert Van Assche

CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS

Marc Ferrante, Laurent Peyrin-Biroulet, Axel Dignass, David T. Rubin, Silvio Danese, Geert R. D'Haens, Kristina Kligys, Sofie Berg, Jasmina Kalabic, Javier Zambrano, Yafei Zhang, Toshimitsu Fujii, Remo Panaccione

CLINICAL INEFFICACY OF GOLIMUMAB IN ULCERATIVE COLITIS PATIENTS IS INDEPENDENT OF IMMUNOGENICITY

Iris Detrez, Annick de Vries, Els Brouwers, Severine Vermeire, Marc Ferrante, Ann Gils

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Silvio Danese, William Sandborn, Edward V. Loftus Jr., Stephen B Hanauer, Stefan Schreiber, Laurent Peyrin-Biroulet, Remo Panaccione, Julian Panés, Filip Baert, Jean-Frederic Colombel, Marc Ferrante, Edouard Louis, Alessandro Armuzzi, Sasikiran Goteti, John Liu, Nael M. Mostafa, Thao Doan, Joel Petersson, Anne M. Robinson

COMPARISON OF GEBOES SCORE AND SIMPLIFIED GEBOES SCORE WITH MAYO ENDOSCOPIC SUBSCORE IN PATIENTS WITH RECENT DIAGNOSIS OF ULCERATIVE COLITIS: A RETROSPECTIVE STUDY.

Aranzazu Jauregui Amezaga, Auke Geerits, Yannick Das, Bart Lemmens, Talat Bessissow, Triana Lobaton Ortega, Marc Ferrante, Raf Bisschops, Karel Geboes, Gert De Hertogh, Severine Vermeire

Item 1 - 10 / 112
1
2 3 4 5 6 7
...
11 12